SCHEMBL16196649

SCHEMBL16196649

Cc1cc(Br)cc(C)c1C1C(=O)C2C3CCC(O3)C2C1=O

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GMNN O75496 1/20 0.36
PPM1B O75688 1/20 0.36
LMNA P02545 1/20 0.36
PPP1CC P36873 1/20 0.36
TFPI2 P48307 1/20 0.36
RAB9A P51151 1/20 0.36
PPP5C P53041 1/20 0.36
PPP1CA P62136 1/20 0.36
PMP22 Q01453 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
TP53 P04637 1/20 0.36
CYP2D6 P10635 1/20 0.36
NFKB1 P19838 1/20 0.36
THPO P40225 1/20 0.36
HPGD P15428 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL516059 1.00 L3MBTL1 (0.38) L3MBTL1SMN1; SMN2KDM4EGMNNPPM1B
SCHEMBL2122883 0.87 L3MBTL1 (0.40) L3MBTL1SMN1; SMN2KDM4EGMNNPPM1B
SCHEMBL15001081 0.80 L3MBTL1 (0.35) L3MBTL1SMN1; SMN2KDM4EGMNNPPM1B
SCHEMBL6727399 0.79 L3MBTL1 (0.38) L3MBTL1SMN1; SMN2KDM4EGMNNPPM1B
SCHEMBL15001080 0.79 L3MBTL1 (0.35) L3MBTL1SMN1; SMN2KDM4EGMNNPPM1B
SCHEMBL9110548 0.79 L3MBTL1 (0.43) L3MBTL1SMN1; SMN2KDM4EGMNNPPM1B
SCHEMBL6727885 0.79 L3MBTL1 (0.35) L3MBTL1SMN1; SMN2KDM4EGMNNPPM1B
SCHEMBL21938530 0.79 L3MBTL1 (0.35) L3MBTL1SMN1; SMN2KDM4EGMNNPPM1B
SCHEMBL22906311 0.79 L3MBTL1 (0.35) L3MBTL1SMN1; SMN2KDM4EGMNNPPM1B
SCHEMBL16196477 0.79 L3MBTL1 (0.35) L3MBTL1SMN1; SMN2KDM4EGMNNPPM1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2785181-B1 2-(SUBSTITUTED-PHENYL)-CYCLOPENTANE-1,3-DIONE COMPOUNDS, AND DERIVATIVES THEREOF SYNGENTA LTD (GB) 2016-08-17 EP disclosed
US-9107415-B2 2-(substituted-phenyl)-cyclopentane-1,3-dione compounds, and derivatives thereof SYNGENTA PARTICPATIONS AG (CH) 2015-08-18 US disclosed
US-20140323303-A1 2-(SUBSTITUTED-PHENYL)-CYCLOPENTANE-1,3-DIONE COMPOUNDS, AND DERIVATIVES THEREOF SYNGENTA PARTICIPATIONS AG (CH) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323303-A1 2-(SUBSTITUTED-PHENYL)-CYCLOPENTANE-1,3-DIONE COMPOUNDS, AND DERIVATIVES THEREOF CNPY2, CBR3, CBR1 L3MBTL1 965/4885SMN1; SMN2 4753/4885KDM4E 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.